Vor Bio (Nasdaq: VOR), a Boston-based clinical-stage biotechnology company focused on autoimmune diseases, announced a USD 75 million private placement led by healthcare investment firm TCGX. The Vor Bio capital raise is intended to fund continued clinical development of telitacicept, the company's lead asset, across multiple autoimmune indications, including ongoing global Phase III trials in generalized myasthenia gravis and primary Sjögren's disease. The company did not engage a placement agent for the transaction, which is expected to close on or about March 30, 2026.
Under the terms of the VOR stock offering, Vor Bio agreed to sell 5,338,078 shares of common stock at USD 14.05 per share. No warrants were disclosed as part of the transaction structure. The financing was led by TCGX, identified as a new investor in the company. TCGX is a healthcare-focused investment firm with teams in San Francisco, Palo Alto, and New York City. Cariad Chester, Managing Partner at TCGX, was quoted in the announcement. No other investors were named in the press release, though the registration rights agreement referenced "investors" in plural form, suggesting additional undisclosed participants. The press release did not indicate insider participation. Concurrently with the securities purchase agreement, Vor Bio entered into a registration rights agreement obligating the company to file a resale registration statement with the SEC covering the shares issued in the placement.
Company overview and pipeline
Vor Bio is headquartered in Boston, Massachusetts, and underwent a corporate transformation in mid-2025. In May 2025, the company halted all clinical and manufacturing operations related to its original engineered stem cell therapy oncology pipeline, reduced headcount by approximately 95%, and initiated a strategic review. In June 2025, Vor Bio entered into an exclusive global license agreement with China-based RemeGen (HKEX: 9995) for telitacicept, a dual-target recombinant fusion protein that inhibits both BAFF (BLyS) and APRIL, two cytokines involved in B cell survival and differentiation. The license covers all territories excluding Greater China. The upfront consideration totaled USD 125 million, comprising USD 45 million in cash and USD 80 million in prefunded warrants sold to RemeGen. Milestone payments exceed USD 4 billion, with tiered royalties on net sales. Concurrently, Vor Bio closed a USD 175 million PIPE financing in June 2025 to fund its new autoimmune disease strategy.
Telitacicept is already approved in China for three autoimmune indications: generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. Vor Bio is currently conducting a global Phase III clinical trial for telitacicept in generalized myasthenia gravis, enrolling patients in the United States, Europe, and South America, with preliminary results expected in the first half of 2027. The company is also advancing telitacicept into Phase III development for primary Sjögren's disease. Proceeds from the Vor Bio TCGX-led USD 75 million private placement will support these Phase III programs, business development activities, and general corporate purposes. Including this transaction, Vor Bio has raised over USD 250 million in equity financing since its June 2025 strategic pivot to autoimmune disease.
Spot something wrong? Report an issue with this article